Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PD-1 Knockout TILs in Advanced Colorectal Cancer
NCT07035002Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of IOV-4001 in colorectal cancer (CRC) (4 arms), sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicity at 12 months and Severe Treatment Related Complications at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
IOV-4001
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07035002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035002.